Unternehmensübersicht
TuHURA Biosciences, Inc. operates as a clinical stage immuno-oncology enterprise dedicated to developing novel technologies specifically for the treatment of cancer immunotherapies. The company focuses on its lead product candidate, IFx2.0, which functions as an innate immune agonist engineered to overcome primary resistance to checkpoint inhibitors. Operating within the Healthcare sector and the Biotechnology industry, the firm targets specialized therapeutic niches requiring significant research and development capital. As of the latest reporting period, the company holds a market capitalization of $115.08M and employs a workforce of 22 individuals. The market cap figure indicates that TuHURA is a small-cap entity, reflecting the high-risk, high-potential nature typical of early-stage biotechnology firms that have not yet generated commercial revenue. The absence of reported annual revenue further contextualizes the company's position as an asset-heavy R&D platform reliant on future milestone achievements to transition into profitability.
Finanzielle Gesundheit
The financial statements reveal a net income (TTM) of $-30,060,332 and an EBITDA of $-28,045,056, while revenue (TTM) is reported as N/A. The substantial negative net income relative to the reported EBITDA gap highlights a significant cost structure burden, likely driven by non-cash charges such as stock-based compensation or impairment expenses common in the biotechnology sector. Free cash flow stands at $-4,757,422, indicating that the company is currently burning cash to fund its operations and research initiatives rather than generating liquidity from core activities. The balance sheet shows available cash of $3.62M against total debt of $700,022, suggesting that while the company carries leverage, it maintains a positive cash position to cover short-term obligations. However, the debt-to-equity ratio of 3.34 signals a highly leveraged capital structure relative to shareholder equity, which amplifies financial risk during periods of market stress. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, which is characteristic of a pre-revenue company with no sales to calculate margins yet. The current ratio is 0.78, indicating that current assets are insufficient to cover current liabilities without relying on external financing or asset liquidation. Return on Equity is -169.2% and Return on Assets is -74.3%, metrics that mathematically reflect the company's ongoing losses and the dilution of shareholder value due to negative earnings relative to the book value of equity and total assets.
Bewertungsanalyse
The valuation metrics present a complex picture with a P/E Ratio (TTM) of N/A due to negative earnings and a Forward P/E of -3.12, which mathematically results from the negative earnings projection. The price-to-book ratio stands at 5.20, indicating that the market values the company's equity at more than five times its book value, a premium often attributed to the potential value of its intellectual property pipeline despite current losses. Price-to-sales and EV/EBITDA ratios are also reported as N/A or negative (-4.01), suggesting that traditional valuation multiples based on earnings or sales are not applicable for a pre-revenue biotechnology firm. The stock's 52-week high was $4.44 and the 52-week low was $0.41, defining a trading range of over ten times. Based on the provided data points, the current market price sits somewhere within this volatile historical range, reflecting the high uncertainty inherent in speculative small-cap biotech equities. The beta value is reported as N/A, implying that either the stock lacks sufficient trading volume to calculate volatility or that the data provider does not list it, making it difficult to assess price volatility relative to the broader market using standard statistical measures.
Growth & Income
Revenue growth (YoY) and earnings growth (YoY) are both listed as N/A, as the company has not yet generated commercial revenue to establish a growth trajectory. Consequently, there is no earnings growth to compare against revenue, and the company is in the investment phase where all cash outflows are directed toward product development rather than shareholder returns. The dividend yield is N/A and the payout ratio is 0.0%, confirming that TuHURA does not distribute dividends to shareholders. Instead of paying dividends, the company reinvests all available capital and raised funds into its immuno-oncology research programs to advance the development of IFx2.0 and other pipeline assets. The overall growth and income profile is defined by zero current income generation and a reliance on external capital markets to fund future expansion until the lead product candidate reaches later stages of clinical development and commercialization.